Navigation Links
ARKRAY, Inc. Long Term Care Division Launches Comprehensive Service Program - Assure(R) Brilliance

EDINA, Minn., Jan. 15 /PRNewswire/ -- ARKRAY, Inc., the world's 5th largest manufacturer of diabetes self-monitoring systems, launches the Assure Brilliance Program – a comprehensive service program for Long Term Care facilities and multi-patient use settings.

Assure® brand blood glucose monitoring systems from ARKRAY have been the leading brand of blood glucose meters in Long Term Care for years. ARKRAY has always been committed to providing excellent services to customers and the Assure Brilliance program is the next step in providing truly comprehensive diabetes management help to over-burdened LTC facilities.

Assure Brilliance consists of three main components – service, diabetes program management, and education. ARKRAY is the only blood glucose meter manufacturer with a dedicated LTC sales force. The company provides on-site training for all shifts, convenient customer service hours for LTC facilities, QA/QC guidance, and extensive training materials, videos, and online resources. The focus on diabetes in Long Term Care has allowed ARKARY to develop an expertise in managing diabetes in LTC – knowledge that is passed along to customers, keeping everyone up-to-date on industry best practices. ARKRAY also offers customers multiple CE courses online at no charge and a quarterly newsletter focused on industry hot buttons such as infection control and F-Tags.

Assure Blood Glucose Meters, including the new auto-code Assure® Platinum meter, are backed by the Assure® Brilliance program to help facilities manage complex diabetes care in their facilities. ARKRAY representatives can do consultations to find how LTC facilities may best benefit from the Assure Brilliance Program.

About ARKRAY USA - ARKRAY, the leader in the Long Term Care blood glucose market, has been a pioneer for nearly 50 years in the field of automated analysis from laboratory and point-of-care systems to home use patient self-testing systems. ARKRAY is one of the few diabetes testing companies in the U.S. market today that undertakes in-house each step of the development process to bring products to market. ARKRAY strongly believes in the relentless innovation of medical technology and focused attention to producing the highest quality products. For patients and health care professionals, this means access to cutting-edge, reliable products and customer-focused service.

For more information: or




Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System
2. ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System
3. ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer
4. Strykers Biotech Division Receives FDA Warning Letter
5. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
6. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
7. California Cryobank Names Richard Jennings President of FamilyCord Division
8. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
9. Vivakor Divisions Continue to Demonstrate Independent Growth
10. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
11. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
Post Your Comments:
(Date:12/1/2015)... Sweden , December 1, 2015 ... Cancer Study Group (IBCSG, Bern ) and ... to be part of a state of the art trial, ... --> --> The study, ... treated with anti-hormonal therapy in combination with palbociclib, a cancer ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical Device ... 22 nd April 2016. --> --> ... --> -->   --> --> ... population and the government back up, the Medical Device is one of the ... . With the aging population and the government back up, the Medical ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... It’s official: Tattoo taboo is a thing of the past. One ... (a whopping one in three aged 18 to 25 is inked). As tattoos transition ... ink. In fact, RealSelf , the world’s largest community for learning and sharing ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... technicians must mark the film for accurate interpretation by the radiologist. The marking ... an inventor from Sacramento, Calif., has found a way to alleviate this problem. ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the Field for Effective Post-Affiliation Integration ,” addresses a main “pain point” for ... deliver the anticipated results, once a deal is signed. This quick-read guidance ...
(Date:12/1/2015)... China (PRWEB) , ... December 01, 2015 , ... Nurotron ... result in its largest order to date. , The order will be from ... systems. Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults ...
Breaking Medicine News(10 mins):